Gsk (GSK) Change in Receivables (2009 - 2023)

Gsk (GSK) has 12 years of Change in Receivables data on file, last reported at -$985.5 million in Q4 2023.

• For the quarter ending Q4 2023, Change in Receivables fell 431.76% year-over-year to -$985.5 million; the trailing twelve-month figure through Dec 2023 stood at -$2.6 billion (down 40.6% YoY), and the FY2023 full-year result was -$987.6 million, down 405.05% from the prior year.
• Change in Receivables was -$985.5 million for Q4 2023 at Gsk, down from -$185.3 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of -$185.3 million in Q4 2022 to a low of -$1.1 billion in Q4 2021.
• A 3-year average of -$740.7 million and a median of -$985.5 million in 2023 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables surged 82.37% in 2022 and plunged 431.76% in 2023, its largest moves.
• Gsk's Change in Receivables stood at -$1.1 billion in 2021, then surged by 82.37% to -$185.3 million in 2022, then plunged by 431.76% to -$985.5 million in 2023.
• Per Business Quant data, the three most recent Change in Receivables figures were -$985.5 million in Q4 2023, -$185.3 million in Q4 2022, and -$1.1 billion in Q4 2021.